Rozrolimupab is a recombinant antibody mixture, specifically containing 25 Rhesus D, or RhD, human antibodies, and is currently under development by Symphogen for the treatment of immune thrombocytopenic purpura (ITP) and for the prevention of hemolytic disease of the newborn (HDN).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.